# Trade Mark Journal No.2026/034 21 August 2026

## WO0000001931075 (5)

Office of origin: Canada

Date of International Registration:23 June 2026
Date of designation in the UK: 23 June 2026

International priority date claimed: 18 June 2026 (Canada) (2483178)

Class 5
  Natural dietary supplements comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function; Pharmaceutical preparations comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function.

SoluPet Inc.

Representative: FASKEN MARTINEAU DUMOULIN LLP, FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, BAY ADELAIDE CENTRE, BOX 20, TORONTO ON M5H 2T6, CANADA